A

Abel, Peter W. See Minneman, 56
Agauyo, L. G.
See El-Pabahany, Eldefawi, Murphy, Triggle, Albuquerque, and Eldernafi, 369
Akaife, Akinori
Ikeda, Stephen R., Brookes, Neville, Pascuzzo, Gary J., Rickett, Daniel L., and Albuquerque, Edson X. The Nature of the Interactions of Pyridostigmine with the Nicotinic Acetylcholine Receptor-Ionic Channel Complex. II. Patch Clamp Studies, 102
See Pascuzzo, Maleque, Shaw, Aronstam, Rickett, and Albuquerque, 86

Albuquerque, E. X.
See El-Pabahany, Eldefawi, Murphy, Agauyo, Triggle, and Eldernafi, 369
See Pascuzzo, Akhie, Maleque, Shaw, Aronstam, and Rickett, 92
See Souccar, Varanda, and Dally, 384
See Souccar, Varanda, Aronstam, and Daly, 395
Aman, Rashid A. See Rosenbaum, Holford, Richards, and Sadée, 242
Angel, Lloyd M. See Miller and Simon, 249
Armitage, I. M. See Pesik, Elledstad, and McGahren, 275, 281
Aronstam, Robert S.
See Pascuzzo, Akhie, Maleque, Shaw, Aronstam, and Rickett, 92
See Souccar, Varanda, and Albuquerque, 395
Audigier, Y. See Castanas, Giraud, Driasi, Bouduresque, Conte-Devolx, and Olivier, 38

B

Bamberger, Michelle J. See Oswald and McLaughlin, 360
Barovskv, Kenneth, Pedone, Carolyn, and Brooker, Gary. Distinct Mechanisms of Forskolin-Stimulated Cyclic AMP Accumulation and Forskolin-Potentiated Hormone Responses in C6-2B Cells, 265
Bartel, Ronada L., and Borchardt, Ronald T. Effects of Adenosine Dialethryde on S-Adenosylhomocysteine Hydrolase and S-Adenosylmethionine-Dependent Transmethylation in Mouse L929 Cells, 418
Bartolucci, Simonetta. See Momparler, Rossi, Bouchard, Vaccaro, and Momparler, 436
Baxter, Diane M.
See Harris, Groh, and Hitzemann, 410
See Harris, Mitchell, and Hitzemann, 401
Belinsky, Steven A., Matsumura, Takakatsu, Kauffman, Frederick C., and Thurman, Ronald D. Rates of Allyl Alcohol Metabolism in Periportal and Pericentral Regions of the Liver Lobule, 158
Benkovic, S. J. See Slier, 294
Berg, Sondra E., and Hakala, Maire T. Relationship of dUMP and Free dUMP Pools to Inhibition of Thymidylate Synthase by 5-Fluorouracil, 303
Billings, Ruth E. Decreased Hepatic 5,10-Methyleneetrahydrofolate Reductase Activity in Mice after Chronic Phenytoin Treatment, 459
Bisgaard, Karen S. See Starke and Mjel، 467
Borchardt, Ronald T. See Bartel, 418
Bouchard, Jacques. See Momparler, Rossi, Vaccaro, Momparler, and Bartolucci, 436
Bouduresque, F. See Castanas, Giraud, Audigier, Driasi, Conte-Devolx, and Olivier, 38
Bradley, Roger D. See Lown, Hanstock, and Scraba, 178
Brattand, Ralph. See Dahlberg, Thalén, Gustafsson, Johansson, Roemphe, and Saartok, 70

Brodersen, Bent. See Honoré, 137
Brooker, Gary. See Barovskv and Pedone, 256
Brookes, Neville. See Akaife, Ikeda, Pascuzzo, Rickett, and Albuquerque, 102
Buckman, Trent D., Sutphin, Mary S., and Eiduson, Samuel. Proteases as Probes of Mitochondrial Monoamine Oxidase Topography in Situ, 165
Bull, H. G. See Casierci, Mumford, Patchett, Thornberrv, and Liang, 287
Bushfield, Mark. See Drummond and Macphee, 201

C

Castanas, E., Giraud, P., Audigier, J-Y., Driasi, R., Bouduresque, F., Conte-Devolx, B., and Olivier, C. Adrenal Medullary Opiate Receptors: Pharmacological Characterization in Bovine Adrenal Medulla and a Human Pheochromocytoma, 38
Catterall, William A. See Postma, 219
See Willow and Kuenzel, 228
Chen, Ming S., Woods, Kathleen L., and Prusoff, William H. Molecular Basis of the Antineoplastic Activity of 3'-Amino-3'-deoxymethyldine, 441
Christie, James L., See Rosen, Rauchman, Ellington, Dahlin, and Nelson, 151
Chuang, De-Maw. See Majewska, 382
Conn, P. Michael, Rogers, Deloris C., and Seay, Sallie G. Biophase Regulation of the Gonadotropin-Releasing Hormone Receptor by Microaggregation and Intracellular Ca2+ Levels, 51
Coon, Minor J. See Koop, 494
Conte-Devolx, B. See Castanas, Giraud, Audigier, Driisi, Bouduresque, and Olivier, 38
Conti-Tronconi, Bianca M. See Saiain, Kageyama, and Guidottii, 327
Cragoe, E. J., Jr. See Vigne, Frelin, and Lazardlusi, 131

D

Dahlberg, Erik, Thalén, Arne, Brattand, Ralph, Gustafsson, Jan-Ake, Johansson, Ulf, Roemke, Karin, and Saartok, Tenu. Correlation between Chemical Structure, Receptor Binding, and Biological Activity of Some Novel, Highly Active, 16α,17α-Acetalt-Substituted Glucocorticoids, 70
Dahlberg, William. See Kufe, Weichselbaum, Egan, and Frarn, 322
Dahlin, David C. See Rosen, Rauchman, Ellington, Christie, and Nelson, 151
Daly, J. W.
See Souccar, Varanda, and Albuquerque, 384
See Souccar, Varanda, Aronstam, and Albuquerque, 395
Dibartolomeis, Michael J., and Jefcoate, Colin R. The Interrelationship of Polycyclic Hydrocarbon Metabolism and Steroidogenesis in Primary Cultures of Bovine Adrenal Cortical Cells, 476
Driasi, R. See Castanas, Giraud, Audigier, Bouduresque, Conte-Devolx, and Olivier, 38
Drummond, Alan H. Bushfield, Mark, and Macphee, Colin H. Thyrotropin-Releasing Hormone-Stimulated [3H]Insitol Metabolism in GH3 Pituitary Tumor Cells: Studies with Lithium, 201
Drummond, Alan H.—Continued
See Macphee, 193
Dumont, Jacques E. See Miot, Erneux, and Wells, 261

E
Egan, E. Michael. See Kufe, Weichselbaum, Dahlberg, and Fram, 322
Ehlert, Frederick J., and Jenden, Donald J. Comparison of the
Muscarinic Receptor Binding Activity of Some Tertiary Amines
and Their Quaternary Ammonium Analogues, 48
Elderson, Samuel. See Buchman and Sutphin, 165
Eldrefawi, A. T. See El-Fakahany, Murphy, Aguayo, Triggle, Albu-
quereque, and Eldrefawi, 369
Eldrefawi, M. E. See El-Fakahany, Eldrefawi, Murphy, Aguayo,
Triggle, and Albuquerque, 369
El-Fakahany, E. E., Eldrefawi, A. T., Murphy, D. L., Aguayo,
L. G., Triggle, D. J., Albuquerque, E. X., and Eldrefawi,
M. E. Interactions of Phencyclidine with Crayfish Muscle Mem-
branes: Sensitivity to Calcium Channel Antagonists and Other
Drugs, 369
Ellestad, G. A. See Fesik, Armitage, and McGahren, 275, 281
Ellington, Sharon P. See Rosen, Rauchman, Dahlin, Christie, and
Nelson, 151
Erneux, Christophe. See Miot, Wells, and Dumont, 261

F
Fain, John N. See Mohell and Wallace, 64
Fesik, S. W.
Magnetic Resonance Studies on the Antibiotic Apovaricin: Confor-
mational Properties in Relation to Antibacterial Activity, 275
Magnetic Resonance Studies on the Interaction of Apovaricin with
Model Receptors of Bacterial Cell Walls, 281
Fischer, Paul H., and Phillips, Anthony W. Antagonism of Feed-
back Inhibition: Stimulation of the Phosphorylation of Thymidine
and 5-Iodo-2'-deoxyuridine by 5-Iodo-5'-amino-2',5'-dideoxyur-
dine, 446
Fram, Robert J. See Kufe, Weichselbaum, Egan, and Dahlberg, 322
Frelin, C. See Vigne, Cragoe, and Lazdunski, 131

G
George, John W. See Pohl, Schulick, and Hight, 318
Giraud, P. See Castanas, Audigier, Driasi, Boudouresque, Conte-De-
volx, and Oliver, 36
Goldman, Mark E., and Kebabian, John W. Apomorphine Enan-
tiomers: Interactions with D-1 and D-2 Dopamine Receptors, 18
Goldstein, Avram
and James, Iain F. Site-Directed Alkylation of Multiple Opioid
Receptors. II. Pharmacological Selectivity, 343
See James, 337
Goldstein, Joyce A., and Linko, Patricia. Differential Induction
of Two 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Inducible Forms of
Cytochrome P-450 in Extrapleural versus Hepatic Tissues, 185
Gould, Robert J., Murphy, Kenneth M. M., and Snyder, Solo-
mon H. Tissue Heterogeneity of Calcium Channel Antagonist
Binding Sites Labeled by [3H]Nitrindipine, 235
Greas, Nahod, and Pullman, Bernard. A Theoretical Study of the
Nonintercalative Binding of Berenil and Stilbamidine to Double-
Stranded (dA-dT), Oligomers, 452
Groh, Gordon I. See Harris, Baxter, and Hitzemann, 410
Guidotti, Alessandro. See Saiani, Kageyama, and Conti-Tronconi,
327
Gustafsson, Jan-Åke. See Dahlberg, Thalén, Brattsand, Johansson,
Roempke, and Saartok, 70

H
Hakala, Maire T. See Berger, 303
Hankin, Hilda. See Maragoudakis, Wasvary, and Gargiulo, 425
Hanstock, Christopher C. See Lown, Bradley, and Scraba, 178
Harris, R. Adron
Baxter, Diane M., Mitchell, Mark A., and Hitzemann, Robert
J. Physical Properties and Lipid Composition of Brain Membranes
from Ethanol Tolerant-Dependent Mice, 401
Groh, Gordon I., Baxter, Diane M., and Hitzemann, Robert
J. Gangliosides Enhance the Membrane Actions of Ethanol and
Pentobarbital, 410
Henry, Jean-Pierre. See Scherman, 113
Hight, Robert J. See Pohl, Schulick, and George, 318
Hiller, Jacob M., Angel, Lloyd M., and Simon, Eric J. Charac-
terization of the Selective Inhibition of the Delta Subclass of
Opioid Binding Sites by Alcohola, 249
Hitzemann, Robert J.
See Harris, Baxter, and Mitchell, 401
See Harris, Groh, and Baxter, 410
Holford, Nicholas H. G. See Rosenbaum, Richards, Aman, and Sadée,
242
Honoré, Bent, and Brodersen, Rolf. Albumin Binding of Anti-
Inflammatory Drugs: Utility of a Site-Oriented versus a Stoichio-
metric Analysis, 137
Hoyer, Daniel, Reynolds, Elwood E., and Molinoff, Perry B.
Agonist-Induced Changes in the Properties of Beta-Adrenergic
Receptors in Intact S49 Lymphoma Cells: Time-Dependent
Changes in the Affinity of the Receptors for Agonists, 209

I
Ikeda, Stephen R. See Akaike, Brookes, Pascuzzo, Rickett, and
Albuquerque, 102

J
James, Iain F.
and Goldstein, Avram. Site-Directed Alkylation of Multiple
Opioid Receptors. I. Binding Selectivity, 337
See Goldstein, 343
Jefcoate, Colin R. See Dibartolomeis, 476
Jekunen, Antti, and Vilpo, Juhan A. 5-Methyl-2'-Deoxycytidine:
Metabolism and Effects on Cell Lethality Studied with Human
Leukemic Cells in Vitro, 431
Jenden, Donald J. See Elhert, 46
Johansson, Ulf. See Dahlberg, Thalén, Brattsand, Gustafsson,
Roempke, and Saartok, 70

K
Kageyama, Hiroyasu. See Saiani, Conti-Tronconi, and Guidotti, 327
Kauffman, Frederick C.
See Belinsky, Matsumura, and Thurman, 158
See Conway, Tsukada, and Thurman, 487
Kebabian, John W. See Goldman, 18
Koop, Dennis R., and Coon, Minor J. Purification of Liver Micros-
omal Cytochrome P-450 Isozymes 3a and 6 from Imidazole-
Treated Rabbits: Evidence for the Identity of Isozyme 3a with the
Form Obtained by Ethanol Treatment, 494
Kuenzel, Elizabeth A. See Willow and Catterall, 228
Kufe, Donald W., Weichselbaum, Ralph, Egan, E. Michael,
Dahlberg, William, and Fram, Robert J. Lethal Effects of 1-
B-D-Arabinofuranosycytosine Incorporation into Deoxyribonu-
cleic Acid during Ultraviolet Repair, 322

L
Langry, Kevin C. See Ortiz de Montellano and Stearns, 310
Lazdunski, M. See Vigne, Frelin, and Cragoe, 131
Liang, T. See Cascieri, Bull, Mumford, Patchett, and Thornberry, 287
Linko, Patricia. See Goldstein, 185
Lown, J. William, Hanstock, Christopher C., Bradley, Roger
D., and Scraba, Douglas G. Interactions of the Antitumor
Agenta Mitoxantrone and Bisantrene with Deoxyribonucleic Acids Studied by Electron Microscopy, 178

M

Macphie, Colin H. and Drummond, Alan H. Thyrotropin-Releasing Hormone Stimulates Rapid Breakdown of Phosphatidylinositol 4,5-bisphosphate and Phosphatidylinositol 4-phosphate in GH3 Pituitary Tumor Cells, 193 See Drummond and Bushfield, 201

Mahan, Lawrence C. See Motulsky, 1

Majewka, Maria Dorota, and Chuang, De-Maw. Modulation by Calcium of γ-Aminobutyric Acid (GABA) Binding to GABA_A and GABA_B Recognition Sites in Rat Brain: Involvement of Different Mechanisms, 352

Maleque, Mohammed A. See Pascuzzo, Akahie, Shaw, Aronstam, Rickett, and Albuquerque, 86

Maragoudakis, Michael E., Wa savvy, James, Hankin, Hilda, and Gargiulo, Paul. Human Placenta Aldose Reductase: Forms Sensitive and Insensitive to Inhibition by Alrestatin, 425

Matsumura, Takakatsu. See Belinsky, Kaufman, and Thurman, 158

Matubayashi, Norihiko. See Mori and Ueda, 123

McGahren, W. J. See Feus, Armitage, and Elledest, 275, 281

McLaughlin, John. See Dorowski and Bamberger, 360

Mellon, William S. Dye-Ligand Interactions with 1,25-Dihydroxyvitamin D3-Receptor Complexes from Chicken Intestine, 79 Specificity of Dye-Ligand Interaction with the Polynucleotide Binding Domain of 1,25-Dihydroxyvitamin D3-Receptor Complexes of Chicken Intestinal Cytosol, 86

Mieyal, John J. See Starke and Bliard, 467

Minneman, Kenneth P., and Abel, Peter W. “Spare” Alpha-Adrenergic Receptors and the Potency of Agonists in Rat Vas Deferens, 56

Miot, Françoise, Erneux, Christophe, Wells, Jack N., and Dumont, Jacques E. The Effects of Alkylated Xanthines on Cyclic AMP Accumulation in Dog Thymus Slices Exposed to Carbamylcholine, 261

Mitchell, Mark A. See Harris, Baxter, and Hitzemann, 401

Moeller, Nina, Wallace, Michael, and Fein, John N. Alpha-Adrenergic Stimulation of Phosphatidylinositol Turnover and Respiration of Brown Fat Cells, 64

Molinoff, Perry B. See Hoyer and Reynolds, 209

Momparler, Louise F. See Momparler, Rossi, Bouchard, Vaccaro, and Bartolucci, 436

Momparler, Richard L., Rossi, Mosé, Bouchard, Jacques, Vaccaro, Carlo, Momparler, Louise F., and Bartolucci, Simonti. Kinetic Interaction of 5-AZA-2'-Deoxycytidine-5'-Monophosphate and Its 5'-Triphosphate with Deoxycytidylic Deaminase, 436

Mori, Takahiko, Matubayashi, Norihiro, and Ueda, Isamu. Membrane Expansion and Inhalation Anesthetics: Mean Excess Volume Hypothesis, 123

Motulsky, Harvey J., and Mahan, Lawrence C. The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action, 1

Mumford, R. A. See Cascieri, Bull, Patchett, Thornberry, and Liang, 287

Murphy, D. L. See El-Fakahany, Eldefrawi, Aguayo, Triggle, Albuquerque, and Eldefrawi, 369

Murphy, Kenneth M. M. See Gould and Snyder, 235

N

Neff, N. H. See Wojcik, 24

Nelson, Sidney D. See Rosen, Rauckman, Ellington, Dahlia, and Christie, 151

Nishimura, Stephen L., Recht, Lawrence D., and Pasternak, Gavril R. Biochemical Characterization of High-Affinity [H]-Opioid Binding: Further Evidence for Mu Sites, 29

Ohizumi, Yasushi. See Tatsumi and Takahashi, 379

Oliver, C. See Castanas, Giraud, Audigier, Drissi, Boudouresque, and Conte-Devolx, 38

Ortiz de Montellano, Paul R., Stearns, Ralph A., and Langry, Kevin C. The Allylisopropylacetamide and Novonal Prosthetic Heme Adducts, 310

Oswald, Robert E., Bamberger, Michelle J., and McLaughlin, James T. Mechanism of Phencyclidine Binding to the Acetylcholine Receptor from Torpedo Electroplaque, 380

P


See Akaike, Iheda, Brooks, Rickett, and Albuquerque, 102

Pasternak, Gavril W. See Nishimura and Rechi, 29

Patchett, A. A. See Cascieri, Bull, Mumford, Thornberry, and Liang, 287

Pedone, Carolyn. See Barosky and Brooker, 256

Phillips, Anthony W. See Fischer, 446

Pohl, Lance R., Schulick, Richard D., Higiet, Robert J., and George, John W. Reductive-Oxygenation Mechanism of Metabolism of Carbon Tetrachloride to Phogene by Cytochrome P-450, 318

Postma, Syndie W., and Catterall, William A. Inhibition of Binding of [3H]2-2-Benzooate to Sodium Channels by Local Anesthetics, 219

Prusoff, William H. See Chen and Woods, 441

Pullman, Bernard. See Gresh, 452

R

Rauckman, Elmer J. See Rosen, Ellington, Dahlia, Christie, and Nelson, 151

Recht, Lawrence W. See Nishimura and Pasternak, 29

Reynolds, Elwood E. See Hoyer and Molinoff, 209

Richards, Mark L. See Rosenbaum, Holford, Aman, and Sadée, 242

Rickett, Daniel L. See Pascuzzo, Akaike, Maleque, Shaw, Aronstam, and Albuquerque, 92

Roempke, Karin. See Dahlberg, Thalén, Brattsand, Gustafsson, Johansson, and Saartok, 70

Rogers, Deloris C. See Conn and Seag, 51


Rossi, Mosé. See Momparler, Bouchard, Vaccaro, Momparler, and Bartolucci, 436

S

Saartok, Tönö. See Dahlberg, Thalén, Brattsand, Gustafsson, Johansson, and Roempke, 70

Sadée, Wolfgang. See Rosenbaum, Holford, Richards, and Aman, 242

Salani, Laura, Kageyama, Hiroysu, Conti-Tronconi, Bianca M., and Guidotti, Alessandro. Purification and Characteriza-
tion of a Bungarotoxin Polypeptide Which Blocks Nicotinic Receptor Function in Primary Culture of Adrenal Chromaffin Cells, 327

Scherman, Daniel, and Henry, Jean-Pierre. Reserpine Binding to Bovine Chromaffin Granule Membranes: Characterization and Comparison with Dihydrotetrazenibazine Binding, 113

Schulick, Richard D. See Pohl, Highet, and George, 318

Scraba, Douglas G. See Lown, Hanstock, and Bradley, 178

Seavy, Sally G. See Conn and Rogers, 51

Seeman, Phillip. See Wreggett, 10

Shaw, Kai-Ping. See Pascuzzo, Akaibe, Maleque, Aronstam, Richett, and Albuquerque, 86

Silver, Paul J., and Stull, James T. Phosphorylation of Myosin Light Chain and Phosphorylase in Tracheal Smooth Muscle in Response to KCl and Carbachol, 267

Simon, Eric J. See Hiller and Angel, 249

Sliker, L. J., and Benkovic, S. J. Inhibition of HKSV28 Cell Growth by 5,11-Methenyltetrahydrofolate, 294

Snyder, Solomon H. See Gould and Murphy, 235

Souccar, C.

Varanda, W. A., Aronstam, R. S., Daly, J. W., and Albuquerque, E. X. Interactions of Gephyrotoxin with the Acetylcholine Receptor-Ionic Channel Complex. II. Enhancement of Desensitization, 395

Varanda, W. A., Daly, J. W., and Albuquerque, E. X. Interactions of Gephyrotoxin with the Acetylcholine Receptor-Ionic Channel Complex. I. Blockade of the Ionic Channel, 394

Spector, Sydney. See Wang and Taniguchi, 349

Starkes, David W., Blisard, Karen S., and Mieyal, John J. Substrate Specificity of the Monoxygenase Activity of Hemoglobin, 467

Stearns, Ralph A. See Ortiz de Montellano and Langry, 310

Stull, James T. See Silver, 267

Sutphin, Mary S. See Buckman and Eiduson, 165

T

Takahashi, Masami. See Tatsumi and Ohizumi, 379

Taniguchi, Takashi. See Wang and Spector, 349

Tatsumi, Masahiro, Takahashi, Masami, and Ohizumi, Yasushi. Mechanism of Palytoxin-Induced [3H]Norepinephrine Release from a Rat Pheochromocytoma Cell Line, 379

Thalen, Arne. See Dahlberg, Brattsand, Gustafsson, Johansson, Roempke, and Saartok, 70

Thornberry, N. A. See Cascieri, Bull Mumford, Patchett, and Liang, 287

Thurman, Ronald G. See Belinsky, Matsumura, and Kauffman, 158

See Conway, Kauffman, and Tsukada, 487

Triggle, D. J. See El-Fakahani, Eldefrawi, Murphy, Aguayo, Albuquerque, and Eldefrawi, 389

Tsukada, T. See Conway, Kauffman, and Thurman, 487

U

Ueda, Issaku. See Mori and Matubayashi, 123

V

Vacca, Carlo. See Momparler, Rossi, Bouchard, Momparler, and Bartolucci, 436

Varanda, W. A. See Souccar, Aronstam, Daly, and Albuquerque, 395

See Souccar, Daly, and Albuquerque, 384


Vilpo, Juhani A. See Jekunen, 431

W

Wallace, Michael. See Mohell and Pain, 64

Wang, James K. T., Taniguchi, Takashi, and Spector, Sydney. Structural Requirements for the Binding of Benzodiazepines to Their Peripheral-Type Sites, 349

Washtien, Wendy L. Increased Levels of Thymidylate Synthetase in Cells Exposed to 5-Fluorouracil, 171

Wasvary, James. See Maragoudakis, Hankin, and Gargiulo, 425

Weichselbaum, Ralph. See Kufe, Egan, Dahlberg, and Fram, 322

Wells, Jack N. See Miot, Erneux, and Dumont, 261

Willow, Max, Kuenzel, Elizabeth A., and Catterall, William A. Inhibition of Voltage-Sensitive Sodium Channels in Neuroblastoma Cells and Synaptosomes by the Anti-convulsant Drugs Diphenylhydantoin and Carbamazepine, 228

Wojcik, W. J., and Neff, N. H. γ-Aminobutyric Acid B Receptors Are Negatively Coupled to Adenylate Cyclase in Brain, and in the Cerebellum These Receptors May Be Associated with Granule Cells, 24

Woods, Kathleen L. See Chen and Prusoff, 441

Wreggett, Keith A., and Seeman, Phillip. Agonist High- and Low-Affinity States of the D2-Dopamine Receptor in Calf Brain: Partial Conversion by Guanine Nucleotide, 10
Notice to Authors Wishing to Submit Manuscripts to

Journal of Pharmacology and Experimental Therapeutics

Molecular Pharmacology

Drug Metabolism and Disposition

The expenses associated with the review of manuscripts submitted to those ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. In order to continue to offer authors the opportunity to publish their original research in our critically reviewed, well-edited, and widely respected journals, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted a uniform manuscript handling fee for each of its journals that publishes original research reports. Therefore, all manuscripts received in the editorial office on or after July 1, 1983, must be accompanied either by a check for $30.00 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the appropriate Editor's office. We regret the necessity of instituting a manuscript handling fee. The Board of Publications Trustees has concluded, however, that this charge represents the fairest and most appropriate manner to defray the costs related to the review of submitted manuscripts. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.
INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, are also inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drugs between two compartments.

Page charges. Authors will be billed at the rate of $30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges may be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to Dr. Joel Hardman, Editor, Molecular Pharmacology, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, U. S. A.

The expenses associated with the review of manuscripts submitted to Molecular Pharmacology and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform handling fees. Therefore, all manuscripts must be accompanied either by a check for $30 (in U. S. funds payable to ASPET) or by a validated purchase order from the author's institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8 1/2 x 11 inches (ca. 215 x 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original figures and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in Molecular Pharmacology represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the Instructions to Authors of the Journal of Biological Chemistry (Vol. 258, pp. 1-11, January 10, 1983). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of Biological Abstracts. References to papers that
have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.


Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, a, b, c, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers after such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (×, O, ⊙, □, ■, △, A, Ø). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Galley proof. The cost of all changes on galley proof, other than printer's errors, will be charged to authors. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Acting Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.